Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Abstract

Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Adverse events can be severe, long-lasting, or both, but most are reversible with appropriate treatment. (Funded by Medarex and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00094653.)

Keywords

Affiliated Institutions

• The Netherlands Cancer Institute NL
• Princess Margaret Hospital NZ
• University Hospital and Clinics US
• Huntsman Cancer Institute US
• Sylvester Comprehensive Cancer Center US
• Hadassah Medical Center IL
• The Christie Hospital GB
• Providence Portland Medical Center US
• University Medical Center US
• German Cancer Research Center DE
• University of Mannheim DE
• University of Colorado Cancer Center US
• Saint Louis University Hospital US
• Bristol-Myers Squibb (United States) US
• Institut Gustave Roussy FR
• Angeles Clinic and Research Institute US
• University of Colorado Denver US
• Moffitt Cancer Center US
• Dana-Farber Cancer Institute US
• Amsterdam UMC Location Vrije Universiteit Amsterdam NL
• Hampton University US
• Vanderbilt University Medical Center US
• Washington University in St. Louis US
• Memorial Sloan Kettering Cancer Center US
• Heidelberg University DE
• Essen University Hospital DE
• Loyola University Medical Center US

Related Publications